A detailed history of Linden Thomas Advisory Services, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Linden Thomas Advisory Services, LLC holds 26,907 shares of CPRX stock, worth $577,962. This represents 0.07% of its overall portfolio holdings.

Number of Shares
26,907
Previous 21,326 26.17%
Holding current value
$577,962
Previous $330 Million 61.93%
% of portfolio
0.07%
Previous 0.05%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

BUY
$15.19 - $21.35 $84,775 - $119,154
5,581 Added 26.17%
26,907 $535 Million
Q2 2024

Jul 10, 2024

BUY
$14.68 - $16.92 $67,278 - $77,544
4,583 Added 27.37%
21,326 $330 Million
Q1 2024

Apr 29, 2024

BUY
$13.18 - $17.11 $74,677 - $96,945
5,666 Added 51.15%
16,743 $267 Million
Q4 2023

Feb 01, 2024

BUY
$11.78 - $17.29 $130,487 - $191,521
11,077 New
11,077 $186 Million

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.21B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Linden Thomas Advisory Services, LLC Portfolio

Follow Linden Thomas Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Linden Thomas Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Linden Thomas Advisory Services, LLC with notifications on news.